Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

The telehealth company Hims & Hers Health is accelerating its international growth strategy, with a new launch in the United Kingdom marking its latest move. This follows closely on the heels of its ...

The investment narrative surrounding Hims & Hers Health, Inc. presents a complex puzzle. On one hand, institutional money is flowing in and the company i ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Sanofi flagged a second delay to an FDA decision for its experimental multiple sclerosis drug and reported disappointing ...